Capricor Therapeutics, Inc. (CAPR) Stock Grade

About Capricor Therapeutics, Inc.'s fundamentals

Capricor Therapeutics is a biotechnology company with a market capitalization of $1.3 billion that is currently unprofitable, having reported a net loss in its latest annual statement with a net margin of 0.0%. The company's revenue declined 100% year-over-year, indicating it is not currently generating commercial revenue from product sales. Standard valuation metrics like P/E ratio and return on equity are not applicable given the company's loss-making status. As a development-stage biotech firm with no dividend, Capricor is dependent on its pipeline progress and capital resources to fund ongoing operations.